COVID-19 continues to be a challenge in a subgroup of patients who, due to their characteristics, have developed a sub-optimal immunization with the vaccination guidelines against SARS-COV-2 and/or are at greater risk of developing a serious disease from this agent. . Some patients with chronic kidney disease (CKD) have this behavior.The development of drugs against SARS-COV-2 has continued in recent months with encouraging results in some contexts. However, patients with advanced CKD have usually been left out of clinical trials, which is why they are generally excluded in the indications on the data sheet. However, in many cases there is experience in the literature that could support its use, especially in situations of severe disease.The development of knowledge about the use of drugs against SARS-COV-2 in patients with CKD requires constant updating and the ease of access to this type of medication is highly variable.The objective of this App is to gather in a schematic and updated way all the evidence on the use of drugs against SARS-COV-2 in chronic kidney disease with the aim of making it an agile and practical tool that helps decision-making.The information collected here is referenced with the highest degree of scientific rigor available in the literature on the date it was updated.
Somane
